Mentored Investigator Grant
(Formerly Ann and Sol Schreiber Mentored Investigator Award)
The Mentored Investigator Grant provides funding for trainees (post-doctoral fellows or clinical fellows) who are working under the supervision of a mentor who is a recognized leader in the field of ovarian cancer research. Applicants must have an MD or a PhD degree. The grant provides a total of $75,000 to be used over one or two years, and will encourage the recipient’s research career in the field of ovarian cancer.
2023 Grant Recipients
- Chae Young Han, PhD, MD Anderson Cancer Center Detection of CA125-Negative Persistent and Recurrent Ovarian Cancer
- Apoorva Uboveja, PhD, University of Pittsburgh A Metabolic-Epigenetic Switch Affects DNA Repair Pathway Choice
- Sonam Mittal, PhD, Medical College of Wisconsin Exosome Loaded eIF4A1 Dependent Translational Reprogramming in Macrophages
- Antonio Delgado-Gonzalez, PhD, Stanford University Mapping the Spatial Proteomic Landscape of Ovarian Tumors
- Joshua Eggold, PhD, University of Pennsylvania Functional Characterization of Distinct Ovarian Cancer Macrophage Subsets
- Bisiayo Fashemi, PhD, Washington University in St. Louis Organoids to Evaluate an Epigenetic Drug Regimen for HR Proficient Ovarian
- Chen Wang, PhD, MD Anderson Cancer Center Epigenetically Targeting Ovarian Cancer Associated Mesenchymal Stem Cells
- Andres Valdivia, PhD, Northwestern University Complement Activation at the Interface Between Cancer Cells and Adipocytes
- Duaa Al-Rawi, MD, PhD, Memorial Sloan Kettering Cancer Center Examining the Early Events in Fallopian Tube Transformation
2022 Grant Recipients
- Thales Nepomuceno, PhD, Moffitt Cancer Center and Research Institute Tackling PARPi sensitivity in HRP and HRD cells
- Zelei Yang, PhD, Dana Farber Cancer Institute Re-engaging the Anti-tumor Immune Response Against Ovarian Cancer
- Imade Williams, PhD, Indiana University Targeting MYC-HSF1 co-Amplification in High Grade Serous Ovarian Cancer
- Erin Wesley, PhD, University of Minnesota Twin Cities Impact of Cytomegalovirus and Inflammation on NK Cells in Ovarian Cancer
- Amrita Salvi, PhD, The University of Illinois at Chicago Investigating the mechanism of action of PHY34 in HGSOC
- Pamela Rojas de Santiago, PhD, University of Pennsylvania Investigating the Therapeutic Potential of CRABP2 in HGSOC
- Veethika Pandey, PhD, University of Pennsylvania Overcoming T Cell Exhaustion in Ovarian Cancer Tumor Microenvironment
- Benjamin Johnson, PhD, Van Andel Research Institute Ovarian Cancer Stem-like Cell Differentiation Trajectories in Single Cells
- Patrick Innamarato, PhD, Moffitt Cancer Center and Research Institute Determination of the Immunogenic Antigen Repertoire in Ovarian Cancer
- Melica Brodeur, MD, Memorial Sloan Kettering Cancer Center Exploiting SMARCA4 Alterations for New Therapeutics in Ovarian Cancers
- Gamze Bildik Elcik, PhD, MD Anderson Cancer Center DIRAS3 Inhibits KRAS and Sensitizes LGSOC Cells to Anti-autophagic Therapy
2021 Grant Recipients
- Anup Singh, PhD, La Jolla Institute for Immunology Studying the Role of BRCA1 in Regulating Heterochromatin Structure and Function in Ovarian Cancer
- Melanie Weigert, PhD, University of Chicago Genome-Wide Profiling of 5-hydroxymethylcytosine on Cell-Free DNA
- Anne M. van Harten, PhD, Thomas Jefferson University Targeted MDM2 Degradation as a Novel Treatment for Ovarian Cancer
- Bojana Stefanovska, PhD, University of Minnesota Twin Cities APOBEC3B and DNA Repair as Synthetic Lethal Combinations in CCOC
- Sammy Ferri-Borgogno, PhD, MD Anderson Cancer Center Spatially-Resolved Cellular and Transcriptome Analyses of Ovarian Cancer
- Sridevi Challa, PhD, UT Southwestern Medical Center Role of Ribosomal Protein Mono(ADP-ribosyl)ation in Protein Quality Control
- Benoît Bragantini, PhD, Mayo Clinic Probing Homologous Recombination DNA Repair Factors in Chromatin by cryo-EM
- Ronja Anugwom, PhD, MD Anderson Cancer Center Determine Resistance Mechanisms to ATR Inhibition in Ovarian Cancers
- Wei Zhou, PhD, The Wistar Institute Targeting the mevalonate pathway in ARID1A-mutated ovarian cancer
- Xueyang Yu, PhD, Massachusetts Institute of Technology Macrophage Control of the Microenvironment Drives HGSOC Progression
2020 Grant Recipients
- David Chapel, MD, Brigham and Women’s Hospital The Migratory Precursor and Serous Carcinogenesis
- Yilun Deng, PhD, University of Texas Health Science Center at San Antonio CD122-Selective IL-2 Complexes as Novel Ovarian Cancer Therapy
- Elizabeth Lee, MD, Dana Farber Cancer Institute Phase II Trial of Gemcitabine+ATR Inhibitor: Translational Studies
- Jianhuang Lin, PhD, The Wistar Institute Targeting ER Stress Pathway in CARM1-Expressing Ovarian Cancer
- Duygu Ozmadenci, PhD, University of California - San Diego Sensitizing Ovarian Cancer to Immunotherapies
- Elizabeth Raupach, PhD, The Translational Genomics Research Institute Oncogenic Consequences of Altered SWI/SNF-RNA Interactions in SCCOHT
- Camilla Salvagno, PhD, Weill Medical College of Cornell University Dissecting How ER Stress Responses Shape Ovarian Cancer Immuno-Environments
- Janice Santiago, PhD, MD Anderson Cancer Center Crizotinib Improves the Therapeutic Efficacy of Olaparib in Ovarian Cancer
- Ignacio Vázquez-García, PhD, Memorial Sloan Kettering Cancer Center Co-Evolution and Dynamics of Malignant and Immune Cells in Ovarian Cancer
- Morozov Yaroslav, PhD, University of Pennsylvania The BRCA1-A as a Determinant of Chemotherapy Response in ATM Mutated Cells
2019 Grant Recipients
- Kristin G. Anderson, PhD, Fred Hutchinson Cancer Research Center Engineering Adoptive T Cell Therapy for Efficacy in Ovarian Cancer
- Alexander Cole, PhD, Magee-Womens Research Institute Investigating Regulators of Quiescence in Epithelial Ovarian Cancer
- Sarah Gitto, PhD, University of Pennsylvania Modeling Autologous TIL Therapy in Novel PARP Resistant PDX Model for Ovarian Cancer
- Guy Katz, MD, PhD, MD Anderson Cancer Center Therapeutic miRNA Targeting for Ovarian Cancer
- Isaac Klein, MD, PhD, Dana Farber Cancer Institute Transcriptional Regulatory Landscape of High Grade Serous Ovarian Cancer
- John Krais, PhD, Fox Chase Cancer Center Examining the Role of RNF168 in BRCA1 Mutant Ovarian Cancer
- Marilyne Labrie, PhD, Oregon Health and Science University Synergistic Lethality of PARP and P13K Pathway Inhibitors in Ovarian Cancer
- Jing Li, MD, PhD, University of Michigan ARID1A Drives Ovarian Cancer Immunotherapy
- Shariska Petersen, MD, University of Kansas Medical Center Research Institute Cyclin E and BRD4 as Markers for a New PARPi Drug Combination
- Alba Rodriguez-Garcia, PhD, University of Pennsylvania Targeting MISIIR with CAR T Cells for the Treatment of Ovarian Cancer
- Elaine Stur, PhD, MD Anderson Cancer Center Re-activating Anti-tumor Immunity Targeting PSEN1 in CAFS in Ovarian Cancer
- Shuai Wu, PhD, The Wistar Institute Synthetic Lethality for ARID1A Mutation in Ovarian Cancer
- Haineng Xu, PhD, University of Pennsylvania A Novel Targeted Therapy for Cyclin E Over Expressing Ovarian Cancers
- Zvi Yaari, PhD, Memorial Sloan Kettering Cancer Center Implantable Nanosensor for Early-Stage Detection of Ovarian Cancer
2018 Grant Recipients
- Damayanti Chakraborty, PhD, Massachusetts General Hospital Understanding Epigenetic Regulation of Copy Number Gains in Ovarian Cancer
- Daniele Chaves-Moreira, PhD, University of Pennsylvania Isolation and Characterization of the PAX8 Transcriptional Complex
- Chin-Chi Chen, PhD, Johns Hopkins University Determining the Role of ARID1A in 53BP1-mediated DNA Damage Repair
- Shih-Hsun Chen, PhD, Beckman Research Institute of the City of Hope Targeting de-poly (ADP-ribosyl)ation for Ovarian Cancer Therapy
- Matthew Dean, PhD, University of Illinois - Chicago The Ovarian Microenvironment in Metastasis of Fallopian Tube Derived Cancer
- Marcela Haro, PhD, Cedars-Sinai Medical Center Cancer Associated Fibroblasts Hinder the B Cell Anti-Tumor Response
- Ye Hu, MD, PhD, Cedars-Sinai Medical Center Reciprocal Roles of CAFs and CD4+ T Cells in Cancer Progression
- Justyna Kanska, PhD, Cedars-Sinai Medical Center Identifying Synthetic Lethal Targets to Mutant p53 in Development of HGSOC
- Goldie Lui, PhD, Fred Hutchinson Cancer Research Center Identifying Novel Targeted Therapies for MYC-driven Ovarian Cancer
- Sarah Stuckelberger, MD, University of Pennsylvania Development of A Novel Syngeneic Model System for Ovarian Cancer Research
- Yinu Wang, PhD, Northwestern University Characterization of Chromatin Nanoarchitecture of Ovarian Cancer Stem Cells
- Shuang Zhang, PhD, New York University School of Medicine Modeling Human HGSOC Using Fallopian Tube Organoid Cultures
2017 Grant Recipients
- Nabanita Chatterjee, PhD, MD Anderson Cancer Center Ovarian Cancer Disrupts Circadian Cortisol Rhythms
- Marion Curtis, PhD, University of Chicago Mediators of Chemosensitivity and Immunotherapy Targets
- Anniina Farkkila, MD, PhD, Dana Farber Cancer Institute Overcoming PARP Inhibitor Resistance in Ovarian Cancer
- Jagmohan Hooda, PhD, University of Pennsylvania Loss of H2Bub1 Rewires Glutamine Metabolism During Progression of HGSOC
- Gilbert Huang, PhD, MD Anderson Cancer Center Targeting Dormant Ovarian Cancer Cells with Peptide Inhibitors of Autophagy
- Dongyu Jia, PhD, Cedars-Sinai Medical Center COL11A Is A Highly Specific Therapeutic Target in Cancer-Activated Stroma
- Venkatesh Krishnan, PhD, Stanford University Omental Macrophages: Drivers of Ovarian Cancer Metastasis
- Xianzhi Lin, PhD, Cedars-Sinai Medical Center Systematic Discovery of LncRNA Interactome in Epithelial Ovarian Cancer
- Beatrice Rondinelli, PhD, Dana Farber Cancer Institute EZH2 Determines PARPi Resistance and Fork Stabilization in Ovarian Tumors
- Priyanka Verma, PhD, University of Pennsylvania BRCA-Independent DNA Repair Pathways in Ovarian Cancer
2016 Grant Recipients
- Jessica Chacon, PhD, University of Pennsylvania Investigating the Role of Immunosuppressive Molecules in Ovarian Cancer
- Song Yi Ko, PhD, MD Anderson Cancer Center A “Trojan Horse” Mechanism That Mediates Resistance to Anti-VEGF Therapy
- Jill Madden, PhD, Inc., University of Kansas Medical Center Research Institute The Effect of FoxM1 Inhibition on Ovarian Cancer Immunity and Sensitivity
- Abir Mukherjee, PhD, University of Chicago Microenvironment Mediated Stabilization of Hif-1 Alpha in Ovarian Cancer
- Debarshi Roy, PhD, Mayo Clinic Crosstalk Between Glycolytic Pathway Inhibition and Increased Autophagy
- Qian Tan, MD, PhD, Stanford University Activation of Macrophages by Inhibiting CD47 Signaling in Ovarian Cancers
- Ryan Williams, PhD, Memorial Sloan Kettering Cancer Center An Ovarian Cancer Biosensor for Rapid, Non-invasive Disease Detection
- Nur Yucer, PhD, Cedars-Sinai Medical Center Modeling Mullarian HGSC Using BRCA1 Patient Derived iPSCs
- Fan Zhao, PhD, Stanford University Ovarian Cancer Antigen Discovery by Single t-cell Analysis and pHLA Library
- Hengrui Zhu, PhD, The Wistar Institute Epigenetic Targeting of Cancer Stem-like Cells (CSCs) in Ovarian Cancer
2015 Grant Recipients
- Juan Cubillos-Ruiz, PhD, Weill Medical College of Cornell University ER Stress Sensor XBP1 as a Key Regulator of Ovarian Cancer Immunity
- Justyna Filant, PhD, MD Anderson Cancer Center Novel Extra Cellular RNA-based Combinatorial RNA Inhibition Therapy
- Xiaowen Hu, PhD, University of Pennsylvania Long Non-coding RNAs in Epithelia Ovarian Cancer
- Petar Jelinic, PhD, Memorial Sloan Kettering Cancer Center EMSY Suppresses HDR in a BRCA2-interaction-independent Manner
- Zeina Kais, PhD, Dana Farber Cancer Institute Synthetic Lethality Between CCNE1 Amplification and USP1 Inhibition
- Bob McGray, PhD, Roswell Park Cancer Institute Combination Oncolytic Virotherapy/ACT for Ovarian Cancer Treatment
- Alfredo Perales-Puchalt, MD, The Wistar Institute Targeting FSH Receptor with Chimeric Antigen Receptor in Ovarian Cancer
- Nicole Spardy, PhD, Dana Farber Cancer Institute Identification of New Genetic Dependencies in HR-deficient Ovarian Cancers
- Wei Wei, PhD, Massachusetts General Hospital Genomic Analysis to Predict Recurrence in Early Stage Ovarian Cancer
- Oladapo Yeku, MD, PhD, Memorial Sloan Kettering Cancer Center A Phase I Trial Using Chimeric Antigen Receptors in Ovarian Cancer Patients
2014 Grant Recipients
- Nima Aghaeepour, PhD, Stanford University Computationally-guided Characterization of Therapy-resistant Ovarian Tumors
- Raphael Ceccaldi, PharmD, PhD, Dana Farber Cancer Institute A Bioinformatic Screen Identifies POLQ Overexpression in Ovarian Cancers
- Ilana Chefetz, PhD, University of Michigan A Role for ALDH in the Regulation of Necroptosis in Ovarian Cancer Area of research: Therapeutic Targeting
- Ellen Cheon, PhD, Cedars-Sinai Medical Center Collagen-Remodeling Genes Provide a Niche for Ovarian Cancer
- Laura Dillon, PhD, University of Virginia Differential MicroDNA Generation in Ovarian Cancer
- Mo Li, PhD, University of Michigan Mechanism of PARP Inhibitor in Ovarian Cancer Therapy Cancer
- Kyung Hee Noh, PhD, MD Anderson Cancer Center Targeting Adaptive Changes to anti-VEGF Therapy in Ovarian Cancer
- Shailja Pathania, PhD, Dana Farber Cancer Institute Novel Therapeutic Targets for High-Grade Serous Ovarian Carcinoma
- Megan Rice, ScD, Brigham and Women’s Hospital Dietary Fat, Cholesterol, and Ovarian Cancer Risk
- Yang Yang, PhD, Yale University P53 Aggregation: a New Target to Combat Ovarian Cancer Platinum-Resistance
- Chi Lam Au Yeung, PhD, MD Anderson Cancer Center Adipose Tissue Derived Exosomal miRNAs in Ovarian Cancer Progression
- Yuyu Yuyu, PhD, Johns Hopkins University School of Medicine Targeting Spleen Tyrosine Kinase in Chemoresistant Ovarian Cancer
2013 Grant Recipients
- Pradeep Chaluvally-Raghavan, PhD, MD Anderson Cancer Center Role of microRNAs in the 3q26 Amplicon in Ovarian Cancer Pathophysiology and Therapy
- Ronald Chandler, PhD, University of North Carolina - Chapel Hill A Genetically Relevant Mutant Mouse Model of Epithelial Ovarian Cancer
- Diana Hargreaves, PhD, Stanford University Targeting Ovarian Cancer via Cooperative Oncogene Interactions
- Christine Lawson, PhD, University of California - San Diego Testing the FAK and Talin Signaling Linkage in Ovarian Tumor Cell Metastasis
- Teng Ma, MD, PhD, University of Michigan - Ann Arbor The Analysis of NEDD8-activating Enzyme Inhibitor MLN4924 on Ovarian Cancer
- David Pepin, PhD, Massachusetts General Hospital Mechanisms and Markers to Target a Stem Enriched Population of Primary Ovarian Cancer Ascites with the Müllerian Inhibiting Substance
- Yin Wang, PhD, Mayo Clinic Jacksonville Protein Kinase C iota is a Novel Therapeutic Target for Ovarian Cancer Treatment
2012 Grant Recipients
- Bin Guan, PhD, Johns Hopkins University School of Medicine Functional Characterization of the Tumor Suppressor ARID1A in Ovarian Cancer
- Kate Lawrenson, PhD, University of Southern California Modeling Stem Cell Origins of Epithelial Ovarian Carcinomas
- Hanqing Liu, PhD, Fox Chase Cancer Center Targeting Signaling Networks via RNAi to Improve Therapy for Ovarian Cancer
- Ngai Na Co, PhD, MD Anderson Cancer Center The Role of Stromal microRNA 21 in Omental Ovarian Cancer Progression
- See-Hyoung Park, PhD, Stanford University Targeting Ovarian Cancer with Combination of Olaparib and Bepridil
- Melinda Yates, PhD, MD Anderson Cancer Center Unraveling the Initiation of Ovarian Cancer: The BRCA1-Heterozygous Mouse as a Model System
2011 Grant Recipients
- Anirban Mitra, PhD, University of Chicago How Do Cells Near Ovarian Cancer Cells Play a Role in the Disease?
- Gregory Motz, PhD, University of Pennsylvania Stimulating Immune Cells to Fight Ovarian Cancer
- Ruth Perets, MD, PhD, Dana Farber Cancer Institute Trying to Identify the Cell Responsible for Ovarian Cancer
- Sharmistha Sarkar, PhD, MD Anderson Cancer Center Finding a Marker to Detect Early Stage Ovarian Cancer
- Sherry Wu, PhD, MD Anderson Cancer Center Novel Approach to Destroy the Blood Supply that Feeds Ovarian Cancer Tumors
- Tsz-Lun Yeung, PhD, MD Anderson Cancer Center Understanding How Ovarian Cancer Spreads
2008 Grant Recipients
- Weiwei Shan, PhD, MD Anderson Cancer Center Cellular Microenvironment Role in Ovarian Cancer Development
- Takayo Ota, MD, PhD, Mayo Clinic Rochester Characterizing the Genetic Alterations of Aggressive Ovarian Cancer
- Xiaoping He, MD, PhD, Mayo Clinic Rochester Understanding the Molecular Pathways to Chemotherapy Resistance in Ovarian Cancer
- Thuy-Vy Do, PhD, Fox Chase Cancer Center Understanding How Ovarian Cancer Spreads
- Lejla Delic, MD, Cedars-Sinai Medical Center A New Class of Drugs with Potential Against Ovarian Cancer: PARP-inhibitors
2007 Grant Recipients
- Hong Zhang, PhD, Fox Chase Cancer Center Novel Animal Model to Test Drugs Against Ovarian Cancer
- Melissa Merritt, PhD, Brigham and Women’s Hospital How Might Different Tissues in the Ovary Act on Each Other to Induce Cancer
- Mitchell Cheung, PhD, Fox Chase Cancer Center Testing New Therapeutic Agents to Treat Ovarian Cancer
- Kuang-Hung Cheng, PhD, Brigham and Women’s Hospital Animal Model to Study Ovarian Cancer Stem Cells
2006 Grant Recipients
- Ramandeep Rattan, PhD, Mayo Clinic Gene May Be an Early Marker for Ovarian Cancer
- Andres Matoso, MD, Cornell University An Animal Model to Study Major Genetic Alterations in Ovarian Cancer
- Aliza Leiser, MD, Yale University Clinical Implications of the TLR-4MYD88 Pathway in EOC
- Audrey Gagnon, PhD, Brigham and Women’s Hospital New Analytical Tool for Ovarian Cancer Detection
- Adam Clauss, PhD, Dana Farber Cancer Institute Does Ovarian Cancer Originate in the Fallopian Tube?
- Maria Barbolina, PhD, University of Illinois - Chicago Epigenetic Regulation of Metastasis-Associated Gene Expression in EOC
- Tsukasa Baba, Duke University Using Public Resources to Find New Drugs to Treat Resistant Ovarian Cancer
2005 Grant Recipients
- Deyin Xing, MD, PhD, Massachusetts General Hospital Models to Study Hereditary Ovarian Cancer
- Jason Wilken, PhD, Yale University Making an Antibody Treatment for Breast Cancer Work for Ovarian Cancer
- Ritu Salani, MD, Johns Hopkins University School of Medicine DNA Fragments Might be a Way to Screen for Ovarian Cancer
- Joseph Kwong, PhD, Brigham and Women’s Hospital Could Inflammation of Ovarian Cells be the Cause of Ovarian Cancer?
- Amy BonDurant, MD, Duke University Chemical Changes on DNA May Be a Way to Screen for Ovarian Cancer and its Recurrence
- Donna Badgewell, PhD, MD Anderson Cancer Center Developing a Screening Test for Ovarian Cancer
2004 Grant Recipients
- Xiaoyan Ni, PhD, Brigham and Women’s Hospital Biomarkers for Ovarian Cancer
- Brian Barnett, MD, Tulane University Health Sciences Center Depleting Regulatory T Cells to Treat Ovarian Cancer
2003 Grant Recipients
- Monique Spillman, MD, PhD, Duke University Medical Center Role of MAP2K4 Suppressing Metastasis of Serous Ovarian Cancers
- Naomi Hunder, MD, Fred Hutchinson Cancer Research Center Evaluation of Mesothelin as a Taret Antigen in Ovarian Cancer
- Kuan-Chun Huang, PhD, Brigham and Women’s Hospital A Possible New Marker for Drug Resistance of Ovarian Cancer
- Jeremy Chien, PhD, Mayo Clinic How Cell Shape Changes Lead to Metastasis in Ovarian Cancer